Dapiglutide is a synthetic peptide analog engineered with helix-promoting and receptor-binding residues. Sequence composition supports stable secondary structure under physiological conditions. Researchers examine its biophysical properties to understand ligand-receptor interactions. Applications include analog optimization, structure-activity mapping, and targeted-peptide design.
CAT No: R2395
CAS No:2296814-85-0
Synonyms/Alias:Dapiglutide;ZFSPELIJRGIIEX-HLQWLALHSA-N;AT42617;2296814-85-0;
Dapiglutide is a synthetic peptide-based compound designed as a dual agonist for both the glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) receptors. Engineered to combine the beneficial properties of its parent incretin hormones, dapiglutide exhibits a unique profile that makes it highly valuable for a range of research and development applications in metabolic and gastrointestinal sciences. Its structure allows for the modulation of multiple physiological pathways, enabling investigation into complex metabolic processes and gastrointestinal functions. The dual agonistic activity of dapiglutide distinguishes it from single-receptor agonists, offering researchers a versatile tool to explore synergistic effects and novel therapeutic mechanisms in preclinical settings. With its robust stability and well-characterized receptor interactions, dapiglutide provides a reliable foundation for studies focused on peptide-based modulation of metabolic and digestive systems.
Metabolic Disease Research: Dapiglutide is widely utilized in metabolic disease research due to its ability to activate both GLP-1 and GLP-2 receptors, which play pivotal roles in glucose regulation and energy homeostasis. By mimicking the activity of endogenous incretin hormones, this dual agonist facilitates the study of insulin secretion, appetite control, and nutrient absorption. Researchers leverage dapiglutide to dissect the molecular pathways involved in metabolic disorders, such as obesity and insulin resistance, allowing for the identification of novel targets and the evaluation of combination strategies that address multiple aspects of metabolic dysfunction simultaneously.
Gastrointestinal Function Studies: The compound's GLP-2 receptor activity makes it an essential tool in gastrointestinal function studies. Dapiglutide can be employed to investigate intestinal growth, barrier integrity, and nutrient absorption mechanisms. Its dual action enables researchers to assess how simultaneous modulation of GLP-1 and GLP-2 pathways influences gut health, including mucosal repair and adaptation. This is particularly valuable for elucidating the interplay between metabolic and digestive processes, supporting the development of new hypotheses regarding gut-mediated metabolic regulation.
Preclinical Pharmacology: In preclinical pharmacology, dapiglutide serves as a model compound for evaluating the efficacy and safety of dual incretin receptor agonists. Its well-defined pharmacodynamic profile allows for systematic assessment of dose-response relationships, receptor selectivity, and downstream signaling effects in animal models. By providing insights into both acute and chronic physiological responses, dapiglutide helps researchers optimize dosing regimens and predict the translational potential of similar molecules under development.
Peptide Engineering and Optimization: Dapiglutide's engineered structure and dual-targeting mechanism make it a reference standard in peptide engineering and optimization research. Scientists use it to study structure-activity relationships, test novel modifications for enhanced stability, and benchmark the performance of newly designed dual agonists. The knowledge gained from such studies accelerates the development of next-generation peptide therapeutics with improved pharmacokinetic and pharmacodynamic properties.
Biomarker Discovery: Researchers also utilize dapiglutide in biomarker discovery efforts aimed at understanding the molecular effects of dual incretin receptor activation. By analyzing gene expression, protein levels, and metabolic changes in response to the compound, investigators can identify novel biomarkers associated with metabolic and gastrointestinal adaptation. These insights contribute to the refinement of diagnostic tools and the design of targeted interventions in metabolic and digestive health research.
In summary, dapiglutide stands out as a multifaceted research tool across metabolic disease research, gastrointestinal function studies, preclinical pharmacology, peptide engineering, and biomarker discovery. Its dual agonist activity and well-characterized properties enable scientists to explore complex biological processes, optimize peptide-based interventions, and advance the understanding of incretin-based regulation in health and disease. The versatility of dapiglutide continues to drive innovation in metabolic and gastrointestinal research, supporting the development of new strategies for addressing multifactorial disorders at the molecular level.
3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
5. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More